Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 19

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 19
---
 fiscal year ended March 31, 2025 as well as a reduction of tax expense during the fiscal year ended March 31, 2024 due to a favorable resolution of tax contingencies.

#### Core

#### EPS
Core EPS was JPY 491 (JPY +7 and +1.5% AER, -4.3% CER).

<div align='center'>8</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Fiscal Year

Ended March 31, 2025 (Consolidated)

### (2) Consolidated Financial Position
|                   |     | As of | March 31, 2024 |     |     | March 31, 2025 |     | Change |        | Billion JPY |
|:------------------|:----|:------|---------------:|:----|:----|---------------:|:----|:-------|-------:|:------------|
| Total Assets      |     |       |       15,108.8 |     |     |       14,248.3 |     |        | -860.4 |             |
| Total Liabilities |     |       |        7,834.8 |     |     |        7,312.4 |     |        | -522.4 |             |
| Total Equity      |     |       |        7,274.0 |     |     |        6,936.0 |     |        | -338.0 |             |

#### Assets
Total Assets as of March 31, 2025 were JPY 14,248.3 billion ( JPY -860.4 billion). This decrease resulted from the decrease of Intangible Assets ( JPY -643.1 billion) d ue to the effect of amortization and impairment and the effect of foreign currency translation partially offset by acquisition of certain intangible assets, the decrease of Goodwill (JPY -85.6 billion) primarily due to the effect of foreign currency translation, and the decrease of Investments Accounted for Using the Equity Method (JPY -79.0 billion) mainly due to the sale of Teva Takeda Pharma Ltd. shares.

#### Liabilities
Total Liabilities as of March 31, 2025 were JPY 7,312.4 billion ( JPY -522.4 billion ). Total Bonds and Loans were JPY 4,515.